Skip to content

To see the effect of two medicines namely tryushnadi gutika and mustadi kashaya in the disease diabetes

clinical evaluation of effect of tryushnadi gutika and mustadi kashaya in the management of madhumeha w.s.r. to diabetes mellitus(type 2)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024406
Enrollment
80
Registered
2020-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Tryushnadi gutika: 1gm TDS orally before meal Intervention2: Mustadi kashaya: 20ml BD orally before meal Intervention3: Tryushnadi gutika and Mustadi kashaya: 1gm TDS and 20 ml bd orall

Sponsors

Ayurvedic and Unani Tibbia College
Lead Sponsor
Pankaj Raturi
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex aged between 20 to 65 years. If yes in any two of the four: Blood sugar â??fasting > 126 and PP > 200 mg/dl and Glycosylated Haemoglobin (HbA1c) > 6.5% and Subjects having classical symptoms of diabetes with random glucose levels >=200mg/dl ( Diagnosed cases of Type II Diabetics having Glycosylated Haemoglobin (HbA1c) between 6.5-9% without or {with metformin in a dose1g-1.5g/day (for Group-D)}. Subjects who are able to come for follow up on fixed visits and are well aware about the treatment plan. Subjects willing to participate and able to provide written informed consent. Diabetes Mellitus >2 years and

Exclusion criteria

Exclusion criteria: Age below 20 and above 65yrs. Subject of Type-I DM (insulin dependent DM) or Type-II DM on insulin/OHAâ??s other than metformin/ any other AYUSH medication for glucose control. Subjects suffering from the complications of Diabetes mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy etc. which require an urgent treatment. Uncontrolled Hypertensive subjects (BP with or without medication >140/90 mmHg after 5 min. of rest). Subjects with any unstable Heart disease or known cases of MI, unstable angina or CHF. Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction, uncontrolled Pulmonary Dysfunction (asthmatic and COPD subjects). Diabetes Mellitus 10 years. Subjects with current or past diagnosis of malignancy (any malignancy diagnosis in last five years). Subjects who have a recent history or who are currently known to abuse of alcohol or drugs. Subjects suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, TB, AIDS etc). Female subject of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy and for 4 weeks after the end of study therapy. Pregnant / Lactating women. Subject on systemic or oral steroids, oral contraceptive pills or estrogen replacement therapy. Subjects having hypersensitivity to any of the trial drug. Subjects who have completed participation in any other clinical trial during the past six (06) months.

Design outcomes

Primary

MeasureTime frame
Improvement in objective parameters Timepoint: 15,30,45,60,75,90 days

Secondary

MeasureTime frame
Improvement in subjective parametersTimepoint: follow up at every 15 days

Countries

India

Contacts

Public ContactDr H C Gupta

Ayurvedic And Unani Tibbia College

hcgupta.dr@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026